Database for drug metabolism and comparisons, NICEdrug.ch, aids discovery and design
MohammadiPeyhani, H.; Chiappino-Pepe, A.; Haddadi, K.; Hafner, J.; Hadadi, N.; Hatzimanikatis, V.
Show abstract
The discovery of a drug requires over a decade of enormous research and financial investments--and still has a high risk of failure. To reduce this burden, we developed the NICEdrug.ch database, which incorporates 250,000 bio-active molecules, and studied their metabolic targets, fate, and toxicity. NICEdrug.ch includes a unique fingerprint that identifies reactive similarities between drug-drug and drug-metabolite pairs. We use NICEdrug.ch to evaluate inhibition and toxicity by the anticancer drug 5-fluorouracil, and suggest avenues to alleviate its side effects. Clustering based on this fingerprint in statins identified drugs for repurposing. We propose shikimate 3-phosphate for targeting liver-stage malaria with minimal impact on the human host cell. Finally, NICEdrug.ch suggests over 1,300 drugs and food molecules to target COVID-19 and explains their inhibitory mechanisms. The NICEdrug.ch database is accessible online to systematically identify the reactivity of small molecules and druggable enzymes with practical applications in lead discovery and drug repurposing.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Machine learning enables accurate and rapid prediction of active molecules against breast cancer cells 92%
- Bioluminescent zebrafish transplantation model for drug discovery 92%
- Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19 91%
Similar papers in this journal
- Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity 94%
- Rational Discovery of Dual-Action Multi-Target Kinase Inhibitor for Precision Anti-Cancer Therapy Using Structural Systems Pharmacology 94%
- A machine learning and network framework to discover new indications for small molecules 94%
Similar papers in this journal
- Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro 91%
- Novel MBLs inhibitors screened from FDA-approved drug library restore the susceptibility of carbapenems to NDM-1-harbouring bacteria 90%
- Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushrooms 88%
Similar papers in this journal
- Morphological Subprofile Analysis for Bioactivity Annotation of Small Molecules 94%
- Reprogramming Cbx8-Prc1 Function With A Positive Allosteric Modulator 92%
- A competitive activity-based protein profiling platform yields cell wall synthesis inhibitors active against replicating and non-replicating Mycobacterium tuberculosis 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.